bit.bio Wins Honours for Innovation in Synthetic Biology and Exceptional Business Growth.
12.09.2024
bit.bio expands Executive Team with appointment of Przemek Obloj as Chief Financial Officer
bit.bio appoints new Chief Financial Officer, Przemek Obloj
bit.bio launches 16 disease models for neurodegenerative disease
bit.bio launches panel of 16 neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s disea...
bit.bio launches ioAstrocytes
bit.bio launches ioAstrocytes, advancing how scientists can model the human brain.
Bi/ond and bit.bio collaboration generates 3D in vitro model for studying Duchenne Muscular Dystrophy (DMD)
Bi/ond and bit.bio collaboration offers a significant advancement for DMD research and drug discovery.
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to lead fireside chat on programming human cells at SynBioBeta
bit.bio will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio Founde...
bit.bio joins ‘Future Fifty’ as one of UK’s exciting tech companies
bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
bit.bio announces collaboration with The Michael J. Fox Foundation
bit.bio announce first project in multi-year collaboration agreement with The Michael J. Fox Foundation to generate products for r...
bit.bio announced as inaugural partner of Ginkgo's Technology Network
Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...